Calidi Biotherapeutics, Inc. has filed an 8-K report detailing significant changes within its Board of Directors. On March 29, 2026, Allan J. Camaisa, a member of the Board, announced his intention to allow his term to expire at the upcoming annual stockholder meeting. This decision was made without any disagreement regarding the company's operations or policies. Following this announcement, the Board has decided to reduce its size from six to five directors effective at the annual meeting. Additionally, on April 1, 2026, Scott Leftwich was appointed to the Audit Committee of the Board, effective immediately. These changes reflect the company's ongoing governance adjustments as it navigates its strategic direction and operational execution. The filing also confirms that Calidi Biotherapeutics is classified as an emerging growth company, which may influence its reporting and compliance obligations moving forward. The company continues to operate under the regulatory framework set forth by the SEC, ensuring transparency and adherence to legal standards.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.